325 Capital LLC Boosts Stock Holdings in Astrana Health, Inc. $ASTH

325 Capital LLC lifted its stake in Astrana Health, Inc. (NASDAQ:ASTH) by 54.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,839,076 shares of the company’s stock after purchasing an additional 645,123 shares during the period. Astrana Health comprises about 16.0% of 325 Capital LLC’s investment portfolio, making the stock its 2nd largest position. 325 Capital LLC’s holdings in Astrana Health were worth $45,627,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in ASTH. Ameriprise Financial Inc. grew its position in shares of Astrana Health by 231.0% during the 3rd quarter. Ameriprise Financial Inc. now owns 442,314 shares of the company’s stock worth $12,540,000 after buying an additional 308,665 shares in the last quarter. Earnest Partners LLC purchased a new stake in Astrana Health in the fourth quarter valued at about $4,850,000. 1492 Capital Management LLC purchased a new stake in Astrana Health in the fourth quarter valued at about $4,162,000. Insight Wealth Strategies LLC purchased a new stake in Astrana Health in the fourth quarter valued at about $3,514,000. Finally, LPL Financial LLC raised its stake in Astrana Health by 73.6% in the fourth quarter. LPL Financial LLC now owns 309,125 shares of the company’s stock valued at $7,669,000 after buying an additional 131,091 shares during the last quarter. Institutional investors own 52.77% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on ASTH shares. Truist Financial increased their price target on Astrana Health from $38.00 to $47.00 and gave the company a “buy” rating in a research note on Thursday, May 14th. Robert W. Baird set a $45.00 price target on Astrana Health in a research note on Friday, May 8th. Needham & Company LLC increased their price target on Astrana Health from $30.00 to $41.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Barclays upgraded Astrana Health from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $37.00 to $50.00 in a research note on Tuesday, May 26th. Finally, Weiss Ratings upgraded Astrana Health from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 1st. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Astrana Health presently has a consensus rating of “Moderate Buy” and an average target price of $45.00.

Astrana Health Stock Performance

Shares of NASDAQ:ASTH opened at $38.16 on Thursday. The company has a debt-to-equity ratio of 1.20, a current ratio of 1.35 and a quick ratio of 1.35. The business’s 50 day moving average price is $35.64 and its 200-day moving average price is $27.87. The firm has a market capitalization of $2.13 billion, a PE ratio of 62.56 and a beta of 1.00. Astrana Health, Inc. has a 1 year low of $18.08 and a 1 year high of $40.13.

Astrana Health (NASDAQ:ASTH) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.74 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.29 by $0.45. The firm had revenue of $965.10 million for the quarter, compared to analyst estimates of $949.21 million. Astrana Health had a return on equity of 9.22% and a net margin of 0.86%.The business’s revenue was up 55.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.42 earnings per share. As a group, equities research analysts expect that Astrana Health, Inc. will post 1.25 earnings per share for the current fiscal year.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.